

Bibliography:

- Martin, K., Beyer-Westendorf, J., Davidson, B., Huisman, M., Sandset, P., & Moll, S. (2021). Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. *Journal of Thrombosis and Haemostasis*, 19(8), 1874-1882. doi: 10.1111/jth.15358
- Kaplan, R., Tanaka, Y., Passman, R., Fine, M., Rasmussen-Torvik, L., & Vupputuri, S. et al. (2020). Efficacy and Safety of Direct Oral Anticoagulants for Atrial Fibrillation Across Body Mass Index Categories. *Journal Of the American Heart Association*, 9(24). doi: 10.1161/jaha.120.017383
- Witt, D., Nieuwlaat, R., Clark, N., Ansell, J., Holbrook, A., & Skov, J. et al. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Advances*, 2(22), 3257-3291. doi: 10.1182/bloodadvances.2018024893
- Joglar, José A et al. "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." *Circulation* vol. 149,1 (2024): e1-e156. doi:10.1161/CIR.0000000000001193
- Hohnloser SH, Fudim M, Alexander JH, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. *Circulation*. 2019; 139:2292–2300.
- Patel M, Mahaffey K, Garg J et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. *N Engl J Med*. 2011;365(10):883-891.
- Barakat AF, Jain S, Masri A, et al. Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories. *JACC Clin Electrophysiol*. 2021; 7:649–658.
- Nutescu, E., 2022. Apixaban: Drug information. In: UpToDate. [online] Available at: https://www.uptodate.com/contents/apixaban-drug-information?source=auto_suggest&selectedTitle=1~1---1~4---apix&search=apixaban [Accessed 16 August 2024].
- Nutescu, E., 2022. Rivaroxaban: Drug information. In: UpToDate. [online] Available at: https://www.uptodate.com/contents/rivaroxaban-drug-information?source=auto_suggest&selectedTitle=1~4---1~4---riva&search=rivaroxaban [Accessed 16 August 2024].
- Alshammari A, Altuwayjiri A, Alshaharani Z, et al. (October 19, 2020) Warfarin Dosing Requirement According to Body Mass Index. *Cureus* 12(10):e11047. DOI 10.7759/cureus.11047
- Tellor, K., Nguyen, S., Bultas, A., Armbruster, A., Greenwald, N., & Yancey, A. (2018). Evaluation of the impact of body mass index on warfarin requirements in hospitalized patients. *Therapeutic Advances in Cardiovascular Disease*, 12(8), 207-216. doi: 10.1177/1753944718781295
- Wendte, J. (2019). Enoxaparin Rounding.
- By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2023;71(7):2052-2081. doi: 10.1111/jgs.18372
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009 Sep 17;361(12):1139-51. Doi:10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: *N Engl J Med*. 2010 Nov 4;363(19):1877. PMID: 19717844.
- Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2_suppl):e326S-e350S.
- Eliquis package insert. https://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed 9/13/24
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. PMID: 24251359.
- Granger CB, Alexander JH, McMurray JJ, et al. Apixiban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011 Sep 15;365(11):981-82. Doi:10.1056/NEJMoa1107039. Epub 2011 Aug 27. PMID: 21870978.

- Kearon C, Akl EA, Ornelas, J, et al. Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report. *Chest*. 2016;149(2):315-352
- Leung LLK. Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects. *Post TW*, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 3/4/22.
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10. PMID: 21830957.
- Pradaxa package insert. <https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf>. Accessed 9/13/24
- Savaysa package insert. <https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true>. Accessed 9/13/24.
- Xarelto package insert. <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf>. Accessed 9/13/24.
- Ansell, Jack, et al. *Managing Oral Anticoagulation Therapy, Clinical and Operational Guidelines*, 3rd edition. Facts and Comparisons; June 1, 2009
- Dipiro, Joseph T, et al. *Pharmacotherapy, a Pathophysiologic Approach*, 7th edition. New York. McGraw-Hill; 2008. Chapter 21, Venous Thromboembolism; p. 347-353
- Information presented was developed to assist in the delivery of care and is not intended to define the standard of care.